C. Baglini

From the ground up: recognising risk of frailty syndromes and functional decline through foot examination

Kirstyn James, C. Baglini, A. Wershof Schwartz, 2021, BMJ Case Reports.

mTORC1 Couples Nucleotide Synthesis to Nucleotide Demand Resulting in a Targetable Metabolic Vulnerability.

N. Perrimon, D. Kwiatkowski, J. Asara, 2017, Cancer cell.

p62/SQSTM1 Cooperates with Hyperactive mTORC1 to Regulate Glutathione Production, Maintain Mitochondrial Integrity, and Promote Tumorigenesis.

J. Asara, E. Henske, M. Sahin, 2017, Cancer research.

Pencil Beam Scanning Proton Beam Chemoradiotherapy with 5-Fluorouracil and Mitomycin-C for Definitive Treatment of Carcinoma of the Anal Canal: A Multi-institutional Pilot Feasibility Study.

Jeffrey W. Clark, J. Metz, B. Yeap, 2019, International journal of radiation oncology, biology, physics.

Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial.

Jeffrey W. Clark, K. Lillemoe, R. Jain, 2019, JAMA oncology.

Rapamycin-upregulated miR-29b promotes mTORC1-hyperactive cell growth in TSC2-deficient cells by downregulating tumor suppressor retinoic acid receptor β (RARβ)

E. Henske, S. Chan, C. Baglini, 2019, Oncogene.

Results and Molecular Correlates from a Pilot Study of Neoadjuvant Induction FOLFIRINOX Followed by Chemoradiation and Surgery for Gastroesophageal Adenocarcinomas

Jeffrey W. Clark, M. Mino‐Kenudson, R. Heist, 2020, Clinical Cancer Research.

Rapamycin-induced miR-21 promotes mitochondrial homeostasis and adaptation in mTORC1 activated cells

D. Kwiatkowski, J. Asara, E. Henske, 2017, Oncotarget.